Stock Track | Cassava Sciences Inc (SAVA) Soars 5.24% as Stock Rebounds After Massive Plunge on Failed Alzheimer's Drug Trial

Stock Track

Nov 26, 2024

Cassava Sciences Inc (SAVA) stock surged 5.24% in the intraday trading session on Monday, rebounding after a massive 84% plunge the previous day. The biotech firm's shares had plummeted on Friday after disappointing results from a late-stage trial of its experimental Alzheimer's disease drug Simufilam.

The Phase 3 trial failed to meet its co-primary endpoints of cognitive and functional improvement in patients with mild-to-moderate Alzheimer's disease. Simufilam did not show a significant reduction in cognitive or functional decline compared to a placebo during the 52-week study.

Despite the rebound on Monday, Cassava Sciences' stock remains well below its pre-trial levels as investors digest the implications of the failed drug trial. The company's future prospects now hinge on its ability to develop alternative treatments or pivot its research focus.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1138416220"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1138416220\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1138416220?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-26 12:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1138416220","market":"us","top_or_hot":-1,"title":"Stock Track | Cassava Sciences Inc (SAVA) Soars 5.24% as Stock Rebounds After Massive Plunge on Failed Alzheimer's Drug Trial","media":"Stock Track","content":"<p>Cassava Sciences Inc (SAVA) stock surged 5.24% in the intraday trading session on Monday, rebounding after a massive 84% plunge the previous day. The biotech firm's shares had plummeted on Friday after disappointing results from a late-stage trial of its experimental Alzheimer's disease drug Simufilam.</p>\n\n<p>The Phase 3 trial failed to meet its co-primary endpoints of cognitive and functional improvement in patients with mild-to-moderate Alzheimer's disease. Simufilam did not show a significant reduction in cognitive or functional decline compared to a placebo during the 52-week study.</p>\n\n<p>Despite the rebound on Monday, Cassava Sciences' stock remains well below its pre-trial levels as investors digest the implications of the failed drug trial. The company's future prospects now hinge on its ability to develop alternative treatments or pivot its research focus.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Cassava Sciences Inc (SAVA) Soars 5.24% as Stock Rebounds After Massive Plunge on Failed Alzheimer's Drug Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Cassava Sciences Inc (SAVA) Soars 5.24% as Stock Rebounds After Massive Plunge on Failed Alzheimer's Drug Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-11-26 12:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Cassava Sciences Inc (SAVA) stock surged 5.24% in the intraday trading session on Monday, rebounding after a massive 84% plunge the previous day. The biotech firm's shares had plummeted on Friday after disappointing results from a late-stage trial of its experimental Alzheimer's disease drug Simufilam.</p>\n\n<p>The Phase 3 trial failed to meet its co-primary endpoints of cognitive and functional improvement in patients with mild-to-moderate Alzheimer's disease. Simufilam did not show a significant reduction in cognitive or functional decline compared to a placebo during the 52-week study.</p>\n\n<p>Despite the rebound on Monday, Cassava Sciences' stock remains well below its pre-trial levels as investors digest the implications of the failed drug trial. The company's future prospects now hinge on its ability to develop alternative treatments or pivot its research focus.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SAVA","symbol_name":"Cassava Sciences Inc","start_time":0,"source_url":"","article_id":"1138416220","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1138416220","pubTimestamp":1732596274,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Cassava Sciences Inc  stock surged 5.24% in the intraday trading session on Monday, rebounding after a massive 84% plunge the previous day. The biotech firm's shares had plummeted on Friday after disappointing results from a late-stage trial of its experimental Alzheimer's disease drug Simufilam.The Phase 3 trial failed to meet its co-primary endpoints of cognitive and functional improvement in patients with mild-to-moderate Alzheimer's disease. Simufilam did not show a significant reduction in ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SAVA":"Cassava Sciences Inc"},"translate_title":"Cassava Sciences Inc(SAVA)股价在阿尔茨海默氏症药物试验失败后大幅暴跌后反弹，股价飙升5.24%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SAVA":1},"content_text":"Cassava Sciences Inc (SAVA) stock surged 5.24% in the intraday trading session on Monday, rebounding after a massive 84% plunge the previous day. The biotech firm's shares had plummeted on Friday after disappointing results from a late-stage trial of its experimental Alzheimer's disease drug Simufilam.\nThe Phase 3 trial failed to meet its co-primary endpoints of cognitive and functional improvement in patients with mild-to-moderate Alzheimer's disease. Simufilam did not show a significant reduction in cognitive or functional decline compared to a placebo during the 52-week study.\nDespite the rebound on Monday, Cassava Sciences' stock remains well below its pre-trial levels as investors digest the implications of the failed drug trial. The company's future prospects now hinge on its ability to develop alternative treatments or pivot its research focus.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}